State coverage

West Virginia Medicaid and GLP-1 coverage

State Medicaid · 5 documents cited

Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.

At a glance

Other diagnoses only

Medicaid, for obesity: Weight loss is a non-covered service. Wegovy covers heart risk and MASH; Zepbound covers sleep apnea.

Appeal deadline: 90 days from the effective date of the action — which is not the date printed on the notice source

Primary source: West Virginia Bureau for Medical Services, BMS Provider Manual, Chapter 518 Pharmacy Services

Date read: September 2026

American GLP, Publisher · Who writes this site

West Virginia lists weight-loss drugs among its non-covered services, and it attaches a consequence to that word most states leave unsaid: a non-covered service is not something you can take to a state fair hearing at all. That sentence sits directly under the exclusion in the pharmacy chapter of the provider manual, and it is the most consequential line on this page.

The exceptions are not exceptions to the exclusion so much as separate drugs on separate lists. The state's drug list carries three classes built around these molecules and none of them is named for weight: a cardiovascular-event class holding Wegovy, a MASH class holding Wegovy and Rezdiffra, and an obstructive sleep apnea class holding Zepbound alone. Each drug then has its own criteria document, published separately.

Both criteria documents open by restating the exclusion before they list a single requirement. The Wegovy paper says coverage will only be considered for secondary prevention of a cardiovascular event or for MASH; the Zepbound paper says it will only be considered for sleep apnea in adults with obesity. Neither leaves a weight-loss route open.

One thing that simplifies matters here: the answer is the same whether or not you are in a managed care plan. West Virginia carves the pharmacy benefit out of its managed care organizations and runs it through the fee-for-service program, which the provider manual states directly.

What we could verify for West Virginia

Weight-loss drugs are a listed non-covered service, and the manual says what that costs you. Section 518.3 provides that "The following list of drugs, drug products, and related services are not reimbursable," and among them: "Agents used for weight loss, anorexia, or weight gain, including binge-eating disorder." The same section closes with a sentence a denied member needs to read: "Non-covered services are not eligible for a Department of Human Services' (DoHS) Fair Hearing. See 42 § 431.220 When a hearing is required for more information." The chapter is stamped "Effective Date: 7/1/2024" on every page.

West Virginia Bureau for Medical Services, BMS Provider Manual, Chapter 518 Pharmacy Services, effective July 2024 · source

The drug list carries three classes for these drugs and names none of them for weight. Under "MAJOR ADVERSE CARDIOVASCULAR EVENT (MACE) REDUCTION AGENTS, GLP-1 AGONISTS" the entry is "WEGOVY INJECTION, TABLETS." Under "METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)" the preferred agent is "WEGOVY*" and the non-preferred is "REZDIFFRA (resmetirom)*." Under "OBSTRUCTIVE SLEEP APNEA AGENTS" the sole preferred agent is "ZEPBOUND (tirzepatide)*," with the note "*Full PA criteria may be found on the PA Criteria page." The diabetes class is kept separate: "DIABETES AGENTS, GLP-1 AGONISTS" states that "Preferred agents may be authorized with a diagnosis of Diabetes Mellitus Type II" and lists OZEMPIC, TRULICITY and VICTOZA as preferred, with MOUNJARO and RYBELSUS non-preferred. The edition read is headed "Preferred Drug List and Prior Authorization Criteria Q2 v7" and marked "Effective Date: 4/1/2026."

West Virginia Bureau for Medical Services, Office of Pharmacy Services, Preferred Drug List and Prior Authorization Criteria, effective April 2026 · source

The Wegovy criteria state the exclusion before they state a requirement: "Agents used for the purpose of weight loss are typically a benefit exclusion. Coverage of Wegovy will only be considered for the secondary prevention of a cardiovascular event and/or a diagnosis of MASH." The cardiovascular route needs "a documented Body Mass Index (BMI) of 27 kg/m2 or greater," a prescriber "with a clinical specialty certification/degree in cardiology, vascular surgery or neurology," and at least one of prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease shown by an "ankle-brachial systolic pressure index (ABI) of ≤ 0.85 at rest," a revascularization procedure, or an amputation. It also requires that the patient does NOT have "Type 1, type 2 diabetes" or an "HbA1c > 6.5%." "Initial approvals may be authorized for 90 days," and renewal requires "the patient to be taking an appropriate maintenance dose such as 1.7 mg or 2.4 mg per week." The MASH route needs stage 2 or stage 3 fibrosis confirmed by biopsy or elastography and a gastroenterologist or hepatologist. The document is headed "Effective 1/01/2026."

West Virginia Bureau for Medical Services, Office of Pharmacy Services, Prior Authorization Criteria — Wegovy (semaglutide), effective January 2026 · source

Zepbound gets the same opening sentence and one door. "Agents used for the purpose of weight loss are typically a benefit exclusion and not covered by West Virginia Medicaid. Coverage of Zepbound will only be considered for a diagnosis of OSA in adults with obesity." The criteria require "a diagnosis of moderate to severe OSA with a sleep study within the past twelve months confirming an apnea-hypopnea index (AHI) greater than or equal to fifteen events per hour," a "Body Mass Index (BMI) of 30 kg/m² or greater within the past three months," that the patient "has been prescribed or counseled on the use of continuous airway pressure (CPAP) as a potential therapy," and that a patient who also has type 2 diabetes has "been trialed on a preferred GLP-1 (indicated for Type II DM) compliantly for three months and experienced treatment failure." Reauthorization requires tolerance of "AT LEAST a 10 mg maintenance dose" and "a documented weight loss of > 5% or continued to maintain initial 5% weight loss." "Initial approvals may be authorized for 150 days" and "All fills will be limited to a 30-day supply." The document is headed "Effective 7/1/2025."

West Virginia Bureau for Medical Services, Office of Pharmacy Services, Prior Authorization Criteria — Zepbound (tirzepatide), effective July 2025 · source

There is one pharmacy answer in West Virginia, not one per plan. Section 518.15.2 states that "Medicaid members enrolled in the managed care organization plans receive pharmacy benefits from the fee-for-service (FFS) pharmacy program," and that "The FFS pharmacy program covers drugs which are submitted to pharmacies by written, telephonic, or electronic prescriptions." Drugs billed under J codes or HCPCS codes are the exception: those "are covered by the managed care programs and cannot be billed to the fee-for-service program at the point of sale." The same chapter sets out a prescriber-side appeal first — the prescriber "may appeal the decision to the Pharmacy Prior Authorization Vendor Appeals Department in writing (first level appeal)", appeals "will be processed within three business days," and "Any denial resulting from physician review is final," after which "The Medicaid member is notified of this denial and of the right to request a fair hearing."

West Virginia Bureau for Medical Services, BMS Provider Manual, Chapter 518 Pharmacy Services, effective July 2024 · source

West Virginia's hearing window is ninety days, and it does not run from the date on your letter. The rule that governs hearings held by the Board of Review provides: "The time limit for requesting a hearing shall be 90 days from the effective date of the action." A pre-hearing conference carries the same measure — "The time limit for requesting a pre-hearing conference shall be 90 days from the effective date of the adverse action" — and asking for either one before the action takes effect stops it: "If a current Recipient requests a hearing prior to the effective date of the adverse action then the adverse action shall be delayed pending a hearing decision." The manual also states how the count runs: "the day of the act, event, default, or omission from which the applicable period begins to run is not included," and a last day falling on a Saturday, Sunday or legal holiday runs to the next working day. Every page of the version read is marked "Rev. 8/22/2024."

West Virginia Office of Inspector General, Common Chapters Manual 710.16, Hearings Held by Board of Review, effective August 2024 · source

West Virginia is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. West Virginia Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare West Virginia with the rest in the coverage matrix.

Regional insurers that sell plans in West Virginia and have their own page here, quoted from their own policy documents: Highmark Blue Cross Blue Shield. The national insurers are on the insurance index.

If you work for the State of West Virginia

State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: PEIA Preferred Provider Benefit (PPB) plans. Its pharmacy benefit runs through Express Scripts.

Weight-control drugs excluded; lifestyle programs only

PEIA excludes weight-control drugs, and it has never covered weight loss prescriptions outside an ended pilot. It offers a $30-a-month in-person weight program at a BMI of 25 or more, plus the Wondr online program.

The plan-year 2027 exclusions list "Health services and associated expenses intended primarily for the treatment of obesity and morbid obesity, including wiring of the jaw, weight-control programs, weight-control drugs, screening for weight-control programs, and services of a similar nature, except those services provided through the Weight Management Program offered by PEIA"